NASDAQ : ACIU
AC Immune SA — Key statistics
Healthcare · Biotechnology · Switzerland
Last price 2.22 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 220.73M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 220.73M |
| Enterprise Value | 132.54M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 99.43M |
| Shares Outstanding | 99.43M |
| Shares Change (YoY) | +1.25% |
| Shares Change (QoQ) | +6.67% |
| Owned by Insiders (%) | 5.71% |
| Owned by Institutions (%) | 4.73% |
| Float | 39.18M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | 39.07 |
| PS Ratio | 10.19 |
| Forward PS | 23.89 |
| PB Ratio | 5.07 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 6.12 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 0.93 |
| Quick Ratio | 0.89 |
| Debt / Equity | 0.12 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -204.20 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -78.53% |
| Return on Assets (ROA) | -16.04% |
| Return on Invested Capital (ROIC) | -45.93% |
| Return on Capital Employed (ROCE) | -87.12% |
| Weighted Average Cost of Capital (WACC) | 12.60% |
| Revenue Per Employee | $177,619 |
| Profits Per Employee | -$437,794 |
| Employee Count | 122 |
| Asset Turnover | 0.10 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.55 |
| 52-Week Price Change | -42.19% |
| 50-Day Moving Average | 2.61 |
| 200-Day Moving Average | 2.73 |
| Relative Strength Index (RSI) | 36.18 |
| Average Volume (20 Days) | 186,467 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 3.26M |
| Short Previous Month | 3.52M |
| Short % of Shares Out | 7.03% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 16.26 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 21.67M |
| Gross Profit | -35.15M |
| Operating Income | -54.08M |
| Pretax Income | -53.41M |
| Net Income | -53.41M |
| EBITDA | -52.57M |
| EBIT | -54.08M |
| Loss Per Share | -$0.53 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 93.26M |
| Total Debt | 5.08M |
| Net Cash | 88.19M |
| Net Cash Per Share | $0.89 |
| Equity (Book Value) | 43.53M |
| Book Value Per Share | 0.44 |
| Working Capital | -8.46M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -61.29M |
| Capital Expenditures | -721,013 |
| Depreciation & Amortization | 1.48M |
| Net Borrowing | -1.16M |
| Free Cash Flow | -62.01M |
| FCF Per Share | -$0.62 |
Margins
| Measure | Value |
|---|
| Gross Margin | -162.23% |
| Operating Margin | -249.58% |
| Pretax Margin | -246.48% |
| Profit Margin | -246.48% |
| EBITDA Margin | -242.61% |
| EBIT Margin | -249.58% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -1.25% |
| Shareholder Yield | -1.25% |
| Earnings Yield | -23.71% |
| FCF Yield | -28.09% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $8.57 |
| Price Target Difference | 286.04% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (3Y) | 211.24% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -3.94 |
| Piotroski F-Score | n/a |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |